We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00234689
First Posted: October 7, 2005
Last Update Posted: January 30, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sheba Medical Center
  Purpose
Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD

Condition Intervention
Obsessive Compulsive Disorder Drug: Naltrexone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Study Start Date: January 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of OCD
  • Treatment with SSRI for at least 10 weeks with no response

Exclusion Criteria:

  • Suffering from any medical condition
  • treatment with opiates
  • chronic use of drugs
  • Hepatitis or other liver related diseases
  • Incapability to sign an informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00234689


Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Tel Aviv University
Study Chair: Revital Amiaz, MD Tel Aviv University
  More Information

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00234689     History of Changes
Other Study ID Numbers: SHEBA-99-1897-JZ-CTIL
First Submitted: October 6, 2005
First Posted: October 7, 2005
Last Update Posted: January 30, 2008
Last Verified: January 2008

Additional relevant MeSH terms:
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Personality Disorders
Mental Disorders
Anxiety Disorders
Naltrexone
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents